<DOC>
	<DOCNO>NCT02508805</DOCNO>
	<brief_summary>The purpose study assess efficacy safety Neuromultivit ( solution injection ) treatment vertebrogenic radiculopathy L5 , S1 comparison standard therapy . The patient randomise two group : standard therapy group standard therapy plus Neuromultivit group .</brief_summary>
	<brief_title>Safety Efficacy Neuromultivit Treatment Vertebrogenic Radiculopathy</brief_title>
	<detailed_description>Group 1 ( 50 patient ) receive Neuromultivit ( 2 ml per day , i.m . ) 7 day , -Neuromultivit ( 2 ml per day , i.m . ) every day 10 day standard therapy 20 day . Group 2 ( 50 patient ) receive standard therapy 20 day . Standard therapy involve : - Voltaren ( 100 mg prolonged-released film-coated tablet daily ) 20 day - Sirdalud ( 2 mg tablet three time day ) 20 day</detailed_description>
	<mesh_term>Radiculopathy</mesh_term>
	<mesh_term>Diclofenac</mesh_term>
	<mesh_term>Tizanidine</mesh_term>
	<mesh_term>Clonidine</mesh_term>
	<criteria>diagnose vertebrogenic radiculopathy L5 , S1 radicular pain syndrome change low back CT MRI scan minimum 40 mm intensity spontaneous back pain , rat VA scale 1 month exacerbation phase ; nonuse Bgroup vitamins trial negative urine pregnancy test ; Patient Informed Consent tumor , inflammatory infection , neurological disease , imitate symptom radiculopathy concomitant lifethreatening medical condition simultaneous administration acetylsalicylic acid , levodopa , prednisolone ; psychiatric disease epilepsy , alcohol drug addiction pregnancy breastfeed condition prevent CT MRI test , include obesity special device participation clinical study 1 month enrollment .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>September 2015</verification_date>
</DOC>